Not long ago, at the 2021 American Society of Clinical Oncology (ASCO) annual meeting, Alpine Immune Sciences Inc (NASDQ: ALPN), a biotechnology company dedicated to the development of innovative therapies for tumors and autoimmune/inflammatory diseases, announced its CD80 fusion protein The data from the Phase 1 clinical trial of ALPN-202 for the treatment of patients with advanced solid tumors showed that its disease control reached 60%, and the trial did not find safe cases of cytokine risk.